argenx reported FB102 data and discontinued UNITY as argenx stock trades at EUR 741.80

Published on 10/13/2026 at 10:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FB102 met its endpoint at p=0.0176 in a 126-patient study. argenx stock costs EUR 741.80 on October 13, 2026 at Lang & Schwarz.

Key points in brief

argenx reported positive Phase 2 FB102 celiac-disease data and discontinued the UNITY study in Sjogren's disease on October 8, 2026.
The FB102 study met its primary endpoint with p=0.0176 in 126 patients.
argenx stock was at EUR 741.80 at Lang & Schwarz on October 13, 2026, while market capitalization stood at USD 50.5 billion on October 12, 2026.
Second-quarter 2026 revenue was USD 1.54 billion and earnings per share were USD 7.32.

Pop-Art-Comic im Lichtenstein-Stil: Stilisierte Antikörper kämpfen gegen Viren, knalliges Magenta Gelb Cyan und Schwarz, Halbtonpunkte, dynamische Diagonale, keine Texte — Argenx NL0010832176 Immunsystem als Pop-Art-Comic mit Antikörpern die Erreger dynamisch bekämpfen illustriert, Illustration mit AI erstellt.

argenx reported positive FB102 Phase 2 data and discontinued the UNITY Phase 3 study on October 8, 2026, while argenx stock was at EUR 741.80 at Lang & Schwarz on October 13, 2026 at 10:07 a.m. CEST. Business Insider reported that the FB102 trial met its primary endpoint with p=0.0176, while Business Insider reported the UNITY discontinuation after an interim analysis.

Three events shaped the pipeline

On September 3, 2026, Wedbush reiterated an Outperform rating and set a USD 1,150.00 price target, according to MarketBeat. The target provides a dated reference for the valuation debate, but it is denominated in USD and is separate from the EUR quote in Germany.

On October 6, 2026, Halozyme expanded its ENHANZE collaboration with argenx by adding two exclusive targets, increasing argenx's access from six to eight targets, according to Zacks.

The October 8 developments created a mixed pipeline picture: FB102 delivered a positive clinical signal in celiac disease, while the UNITY program for Sjogren's disease was discontinued after the monitoring committee concluded that it could not meet its primary endpoint.

What does the latest data mean?

The FB102 result came from a 126-patient Phase 2 study and measured the change in the villus-height-to-crypt-depth ratio at Day 78. The clinical figure gives the program a concrete development milestone, but the UNITY decision removes one late-stage opportunity for efgartigimod in Sjogren's disease.

argenx's operating base was larger in the second quarter of 2026: revenue reached USD 1.54 billion and earnings per share reached USD 7.32, according to The Stock Observer. The same report said earnings per share exceeded consensus of USD 5.86 by USD 1.46, giving investors a quantified comparison alongside the clinical updates.

Stock quote and upcoming date

argenx stock was trading at EUR 741.80 at Lang & Schwarz on October 13, 2026 at 10:07 a.m. CEST. The finance quote showed a market capitalization of USD 50.5 billion and a 52-week range of USD 661.85 to USD 1,072.75 as of October 12, 2026.

The next reported earnings date is October 21, 2026, according to CNN. That date will put the recent clinical developments alongside the company's next financial update.

The further course of trading is shown by the continuously updated real-time quote of argenx stock.